{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:18:11Z","timestamp":1791310691195,"version":"4.3.1"},"reference-count":29,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,7,25]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Replacing rituximab with ofatumumab in second-line therapy for intermediate grade lymphoma does not increase toxicity; ORR\/CR are encouraging. An ongoing randomized phase III trial will compare rituximab with ofatumumab, combined with chemotherapy, in relapsed or refractory DLBCL.<\/jats:p>","DOI":"10.1182\/blood-2012-12-472027","type":"journal-article","created":{"date-parts":[[2013,5,22]],"date-time":"2013-05-22T00:38:42Z","timestamp":1369183122000},"page":"499-506","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":59,"title":["Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma"],"prefix":"10.1182","volume":"122","author":[{"given":"Matthew J.","family":"Matasar","sequence":"first","affiliation":[{"name":"Lymphoma and Adult Bone Marrow Transplant Services, Memorial Sloan-Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine, New York-Presbyterian Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron S.","family":"Czuczman","sequence":"additional","affiliation":[{"name":"Lymphoma\/Myeloma Service, Roswell Park Cancer Institute, Buffalo, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alma","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fennessy","sequence":"additional","affiliation":[{"name":"Oncology Medicines Development Center, GlaxoSmithKline, Middlesex, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Shea","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of North Carolina, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Spitzer","sequence":"additional","affiliation":[{"name":"Center of Excellence for Hematological Malignancies and Transplantation, Bon Secours St. Francis Hospital, Greenville, SC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, University of Miami, Miami, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Joyce","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Henkel","sequence":"additional","affiliation":[{"name":"Lymphoma and Adult Bone Marrow Transplant Services, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Liao","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, Research Triangle Park, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Edvardsen","sequence":"additional","affiliation":[{"name":"Oncology Medicines Development Center, GlaxoSmithKline, Collegeville, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne C.","family":"Jewell","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, Research Triangle Park, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Fecteau","sequence":"additional","affiliation":[{"name":"Oncology Medicines Development Center, GlaxoSmithKline, Collegeville, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra P.","family":"Singh","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modeling & Simulation, GlaxoSmithKline, King of Prussia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen","family":"Lisby","sequence":"additional","affiliation":[{"name":"Medical Department, Genmab A\/S, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig H.","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Lymphoma and Adult Bone Marrow Transplant Services, Memorial Sloan-Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine, New York-Presbyterian Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"22","key":"2019111816262131500_B1","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.","volume":"23","author":"Sehn","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111816262131500_B2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.clml.2011.03.012","article-title":"Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data.","volume":"11","author":"Komrokji","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"27","key":"2019111816262131500_B3","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"47","key":"2019111816262131500_B4","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"issue":"4","key":"2019111816262131500_B5","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2141.2011.08966.x","article-title":"Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.","volume":"156","author":"Barth","year":"2012","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111816262131500_B6","doi-asserted-by":"crossref","first-page":"822","DOI":"10.4049\/jimmunol.181.1.822","article-title":"Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.","volume":"181","author":"Beum","year":"2008","journal-title":"J Immunol"},{"issue":"21","key":"2019111816262131500_B7","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2010.27.9836","article-title":"Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.","volume":"28","author":"Cheson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111816262131500_B8","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"issue":"16","key":"2019111816262131500_B9","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood-2011-09-378323","article-title":"Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.","volume":"119","author":"Czuczman","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2019111816262131500_B10","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","article-title":"First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial.","volume":"111","author":"Hagenbeek","year":"2008","journal-title":"Blood"},{"issue":"16","key":"2019111816262131500_B11","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1016\/j.molimm.2007.06.022","article-title":"Spinning disk confocal fluorescent microscopy (SDCFM) analyses of complement activation promoted by anti-CD20 mAbs rituximab and ofatumumab (HuMax-CD20).","volume":"44","author":"Taylor","year":"2007","journal-title":"Mol Immunol"},{"issue":"5","key":"2019111816262131500_B12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111816262131500_B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials.","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"1","key":"2019111816262131500_B14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"18","key":"2019111816262131500_B15","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"issue":"19","key":"2019111816262131500_B16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bbmt.2012.08.013","article-title":"Phase II trial of 131-iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma.","author":"Vose","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111816262131500_B17","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","article-title":"BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients.","volume":"118","author":"Visani","year":"2011","journal-title":"Blood"},{"issue":"30","key":"2019111816262131500_B18","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma.","author":"Gisselbrecht","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111816262131500_B19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/annonc\/mdh093","article-title":"Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.","volume":"15","author":"Jermann","year":"2004","journal-title":"Ann Oncol"},{"issue":"10","key":"2019111816262131500_B20","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"issue":"12","key":"2019111816262131500_B21","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1080\/10428190600926572","article-title":"DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis.","volume":"47","author":"Mey","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111816262131500_B22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2007-08-108415","article-title":"Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed\/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.","volume":"111","author":"Vellenga","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2019111816262131500_B23","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3109\/10428194.2012.656629","article-title":"Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma.","volume":"53","author":"Elstrom","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"54","key":"2019111816262131500_B24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/10428194.2012.710328","article-title":"Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma.","author":"Forero-Torres","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"15s","key":"2019111816262131500_B25","article-title":"Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [abstract 8069].","volume":"28","author":"Haioun","year":"2010","journal-title":"J Clin Oncol"},{"issue":"31","key":"2019111816262131500_B26","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","article-title":"The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study.","volume":"29","author":"Thieblemont","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111816262131500_B27","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3324\/haematol.13440","article-title":"R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL\/TAMO study.","volume":"93","author":"Mart\u00edn","year":"2008","journal-title":"Haematologica"},{"issue":"8","key":"2019111816262131500_B28","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/annonc\/mdm133","article-title":"Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.","volume":"18","author":"El Gnaoui","year":"2007","journal-title":"Ann Oncol"},{"issue":"4","key":"2019111816262131500_B29","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3816\/CLML.2010.n.055","article-title":"Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed\/refractory B-cell non-Hodgkin lymphoma.","volume":"10","author":"Lignon","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/122\/4\/499\/1372889\/499.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/122\/4\/499\/1372889\/499.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T16:26:36Z","timestamp":1574094396000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/122\/4\/499\/31828\/Ofatumumab-in-combination-with-ICE-or-DHAP"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,25]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-12-472027","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718012191.793481187","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,25]]}}}